Register Login

Allakos Inc (ALLK)

  • Event
  • July 25, 2022, 20:09 UTC

(85% Positive) Allakos Inc. (ALLK) Announces Enrollment Update for directors Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 3:56 p.m.

    📋 Allakos Inc. (ALLK) - Clinical Trial Update

    Filing Date: 2022-07-25

    Accepted: 2022-07-25 16:09:26

    Event Type: Clinical Trial Update

    Event Details:

    Allakos Inc (ALLK) Announces Clinical Trial Update Allakos Inc (ALLK) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: directors
    • Diseases/Conditions: Intuitive Surgical
    • Clinical Stage: clinical trial
    • Collaboration: the American Academy of Orthopaedic Surgeons
      • targeting of cells involved in disease pathogenesis and, in the setting of allergy and inflammation, has the potential to result in broad inhibition of inflammatory cells. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Lirentelimab selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. Inappropriately activated mast cells and eosinophils have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Allakos is developing lirentelimab for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and potentially additional indications. Lirentelimab has received orphan disease status for EG, EoD, and EoE from the U.S. Food and Drug Administration (the “FDA”). AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. AK006 appears to provide deeper mast cell inhibition than lirentelimab and, in addition to its inhibitory activity, reduce mast cell numbers. Allakos plans to begin human studies with AK006 in the first half of 2023
      • targeting; Allakos’ ability to advance additional product candidates beyond lirentelimab; Allakos’ ability to obtain additional capital to finance its operations; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on March 1, 2022

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Allakos Inc
    • CIK: 0001564824
    • Ticker Symbol: ALLK
    • Period End Date: 2022-07-21
    • Document Type: 8-K

Search

News categories